Pazopanib as First Line Treatment for Solitary Fibrous Tumours: The Royal Marsden Hospital Experience

Clinical Sarcoma Research - United Kingdom
doi 10.1186/s13569-015-0022-2
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Retroperitoneal Solitary Fibrous Tumor: Surgery as First Line Therapy

Clinical Sarcoma Research
Oncology
2015English

Pazopanib in the Treatment of Advanced Solitary Fibrous Tumour – Authors' Reply

The Lancet Oncology
Oncology
2019English

Prognostic Factors and Treatment Outcomes in Patients With Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) Experience

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Second Experience

American Journal of Hematology
Hematology
2018English

Clinical Benefit of Patients With Advanced Adrenocortical Carcinoma (Acc) Treated in Phase I Clinical Trials: The Royal Marsden Hospital (Rmh) Experience

Endocrine Abstracts
2016English

Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Single Patient Experience

American Journal of Hematology
Hematology
2017English

Pazopanib as a Second Line Treatment for Uterine and Ovarian Carcinosarcoma: A Single Institutional Study

Journal of Gynecologic Oncology
MedicineGynecologyOncologyObstetrics
2017English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy